- Home
- NPT vs ADAG Comparison
NPT vs ADAG Comparison
Compare NPT & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NPT | ADAG |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | China | China |
| Employees | N/A | N/A |
| Industry | Specialty Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.5M | 146.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | NPT | ADAG |
|---|---|---|
| Price | $6.13 | $4.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 394.5K | 227.3K |
| Earning Date | 11-18-2025 | 03-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $3,688.61 |
| Revenue Next Year | N/A | $17.39 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.14 | $1.33 |
| 52 Week High | $22.38 | $4.58 |
Technical Indicators
Market Signals| Indicator | NPT | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 38.76 | 62.98 |
| Support Level | $4.58 | $1.69 |
| Resistance Level | $6.42 | $4.58 |
| Average True Range (ATR) | 2.23 | 0.50 |
| MACD | -1.33 | 0.02 |
| Stochastic Oscillator | 2.03 | 70.04 |
Price Performance
Historical ComparisonAbout NPT Texxon Holding Limited Ordinary shares
Texxon Holding Ltd provides technology-enabled supply chain management services to customers in the plastics and chemical industries in East China. The company operates through two segments: Supply Chain Trading and Plastic Manufacturing. Its services include procurement, logistics, payments, and fulfillment for Chinese SMEs, and all revenue is generated from operations within the People's Republic of China.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.